Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 949.05 INR 0.82% Market Closed
Market Cap: 955B INR
Have any thoughts about
Zydus Lifesciences Ltd?
Write Note

Intrinsic Value

The intrinsic value of one ZYDUSLIFE stock under the Base Case scenario is 644.39 INR. Compared to the current market price of 949.05 INR, Zydus Lifesciences Ltd is Overvalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZYDUSLIFE Intrinsic Value
644.39 INR
Overvaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Zydus Lifesciences Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZYDUSLIFE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZYDUSLIFE?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Zydus Lifesciences Ltd

Provide an overview of the primary business activities
of Zydus Lifesciences Ltd.

What unique competitive advantages
does Zydus Lifesciences Ltd hold over its rivals?

What risks and challenges
does Zydus Lifesciences Ltd face in the near future?

Has there been any significant insider trading activity
in Zydus Lifesciences Ltd recently?

Summarize the latest earnings call
of Zydus Lifesciences Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zydus Lifesciences Ltd.

Provide P/S
for Zydus Lifesciences Ltd.

Provide P/E
for Zydus Lifesciences Ltd.

Provide P/OCF
for Zydus Lifesciences Ltd.

Provide P/FCFE
for Zydus Lifesciences Ltd.

Provide P/B
for Zydus Lifesciences Ltd.

Provide EV/S
for Zydus Lifesciences Ltd.

Provide EV/GP
for Zydus Lifesciences Ltd.

Provide EV/EBITDA
for Zydus Lifesciences Ltd.

Provide EV/EBIT
for Zydus Lifesciences Ltd.

Provide EV/OCF
for Zydus Lifesciences Ltd.

Provide EV/FCFF
for Zydus Lifesciences Ltd.

Provide EV/IC
for Zydus Lifesciences Ltd.

Show me price targets
for Zydus Lifesciences Ltd made by professional analysts.

What are the Revenue projections
for Zydus Lifesciences Ltd?

How accurate were the past Revenue estimates
for Zydus Lifesciences Ltd?

What are the Net Income projections
for Zydus Lifesciences Ltd?

How accurate were the past Net Income estimates
for Zydus Lifesciences Ltd?

What are the EPS projections
for Zydus Lifesciences Ltd?

How accurate were the past EPS estimates
for Zydus Lifesciences Ltd?

What are the EBIT projections
for Zydus Lifesciences Ltd?

How accurate were the past EBIT estimates
for Zydus Lifesciences Ltd?

Compare the revenue forecasts
for Zydus Lifesciences Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zydus Lifesciences Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zydus Lifesciences Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zydus Lifesciences Ltd compared to its peers.

Compare the P/E ratios
of Zydus Lifesciences Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Zydus Lifesciences Ltd with its peers.

Analyze the financial leverage
of Zydus Lifesciences Ltd compared to its main competitors.

Show all profitability ratios
for Zydus Lifesciences Ltd.

Provide ROE
for Zydus Lifesciences Ltd.

Provide ROA
for Zydus Lifesciences Ltd.

Provide ROIC
for Zydus Lifesciences Ltd.

Provide ROCE
for Zydus Lifesciences Ltd.

Provide Gross Margin
for Zydus Lifesciences Ltd.

Provide Operating Margin
for Zydus Lifesciences Ltd.

Provide Net Margin
for Zydus Lifesciences Ltd.

Provide FCF Margin
for Zydus Lifesciences Ltd.

Show all solvency ratios
for Zydus Lifesciences Ltd.

Provide D/E Ratio
for Zydus Lifesciences Ltd.

Provide D/A Ratio
for Zydus Lifesciences Ltd.

Provide Interest Coverage Ratio
for Zydus Lifesciences Ltd.

Provide Altman Z-Score Ratio
for Zydus Lifesciences Ltd.

Provide Quick Ratio
for Zydus Lifesciences Ltd.

Provide Current Ratio
for Zydus Lifesciences Ltd.

Provide Cash Ratio
for Zydus Lifesciences Ltd.

What is the historical Revenue growth
over the last 5 years for Zydus Lifesciences Ltd?

What is the historical Net Income growth
over the last 5 years for Zydus Lifesciences Ltd?

What is the current Free Cash Flow
of Zydus Lifesciences Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zydus Lifesciences Ltd.

Business Breakdown

Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical landscape, rooted in its rich history and unwavering commitment to innovation. Founded in 1952, the company has evolved from a small enterprise into a global entity, driven by its ambition to provide high-quality and affordable healthcare solutions. With a diverse portfolio that encompasses both generic and branded pharmaceuticals, biosimilars, and consumer health products, Zydus has positioned itself as a key contributor to addressing pressing health needs worldwide. Its state-of-the-art manufacturing facilities and robust R&D capabilities reflect a deep investment in creating cutting-edge therapies that appeal to a growing...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zydus Lifesciences Ltd

Current Assets 115B
Cash & Short-Term Investments 20.5B
Receivables 60.5B
Other Current Assets 34.1B
Non-Current Assets 177.8B
Long-Term Investments 9.7B
PP&E 69.1B
Intangibles 78.8B
Other Non-Current Assets 20.2B
Current Liabilities 53.4B
Accounts Payable 21.3B
Accrued Liabilities 12.7B
Short-Term Debt 7.7B
Other Current Liabilities 11.8B
Non-Current Liabilities 41.1B
Long-Term Debt 251m
Other Non-Current Liabilities 40.8B
Efficiency

Earnings Waterfall
Zydus Lifesciences Ltd

Revenue
206.2B INR
Cost of Revenue
-61.4B INR
Gross Profit
144.8B INR
Operating Expenses
-93.9B INR
Operating Income
50.8B INR
Other Expenses
-8.9B INR
Net Income
41.9B INR

Free Cash Flow Analysis
Zydus Lifesciences Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 FY25, the company achieved substantial growth across all segments, with consolidated revenues rising 20% to INR 52.4 billion. The U.S. business surged 30%, driven by product expansions and an increasing portfolio. Margins improved, with EBITDA rising 28% and the margin touching 27.9%. Key initiatives include a joint venture focused on eco-friendly protein production and successful acquisitions like Naturell India. Guidance suggests continued double-digit growth, with FY25 revenue forecasts in the high teens and stable EBITDA margins expected. The innovation pipeline remains robust, with several new product launches anticipated in FY26.

What is Earnings Call?
Fundamental Scores

ZYDUSLIFE Profitability Score
Profitability Due Diligence

Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Year Average ROE
Positive Free Cash Flow
Positive Net Income
62/100
Profitability
Score

Zydus Lifesciences Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

ZYDUSLIFE Solvency Score
Solvency Due Diligence

Zydus Lifesciences Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Negative Net Debt
78/100
Solvency
Score

Zydus Lifesciences Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZYDUSLIFE Price Targets Summary
Zydus Lifesciences Ltd

Wall Street analysts forecast ZYDUSLIFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZYDUSLIFE is 1 080.22 INR with a low forecast of 494.9 INR and a high forecast of 1 449 INR.

Lowest
Price Target
494.9 INR
48% Downside
Average
Price Target
1 080.22 INR
14% Upside
Highest
Price Target
1 449 INR
53% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZYDUSLIFE?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ZYDUSLIFE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ZYDUSLIFE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd

Country

India

Industry

Pharmaceuticals

Market Cap

955B INR

Dividend Yield

0.32%

Description

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,743 full-time employees. The firm is focused on delivering care and nurturance for the patients, backed by science and cutting-edge technology. The firm has a pipeline for Biologics and Vaccines. The firm offers Lipaglyn to treat diabetic dyslipidemia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The firm in collaboration with Medicines for Malaria Venture (MMV) is developing ZY19489, a single dose cure for Malaria. The Company’s novel oral small molecule, ZYIL1, is an NLRP3 inhibitor candidate. Its ZyCoV-D is a plasmid Deoxyribonucleic acid (DNA) Vaccine for human use. The firm provides Twinrab, which is a novel biological entity for rabies post-exposure prophylaxis. The firm has operations globally and is present in approximately 55 countries worldwide, with 36 manufacturing plants and eight research and development centers.

Contact

GUJARAT
Ahmedabad
Zydue Tower, Satellite Cross Road
+917926868100
www.zyduslife.com

IPO

1995-05-15

Employees

23 743

Officers

MD & Executive Director
Dr. Sharvil Pankajbhai Patel
COO & Executive Director
Dr. Ganesh Narayan Nayak
President & CEO of America
Mr. Punit Patel
Chief Financial Officer
Mr. Nitinkumar Dalsukhray Parekh
Head of Investor Relations
Mr. Arvind Bothra
Company Secretary & Compliance Officer
Mr. Dhaval Narendra Soni

See Also

Discover More
What is the Intrinsic Value of one ZYDUSLIFE stock?

The intrinsic value of one ZYDUSLIFE stock under the Base Case scenario is 644.39 INR.

Is ZYDUSLIFE stock undervalued or overvalued?

Compared to the current market price of 949.05 INR, Zydus Lifesciences Ltd is Overvalued by 32%.

Back to Top